


Sapyen Appoints Industry Veteran Andrew Shine as Director of Commercial Sales

Sapyen appoints industry veteran Andrew Shine as Director of Commercial Sales to drive APAC growth, expanding clinic adoption of its male fertility test.

MELBOURNE, VICTORIA, AUSTRALIA, March 17, 2025 /EINPresswire.com/ -- Sapyen has appointed Andrew Shine as Director of Commercial Sales, reinforcing its position as the global leader in male fertility testing. With a career spanning Virtus Health, Monash IVF, City Fertility, Sonic Healthcare, and Cryosite, Andrew has been at the forefront of major shifts in fertility diagnostics, scaling businesses and driving commercial adoption of new reproductive health technologies.



At Sapyen, Andrew will drive the commercial growth of the Sapyen <u>Male Fertility Test</u> Kit, the most advanced male fertility test on the market. Built on <u>SPX72</u>, the world's first sperm



Sapyen has solved one of the biggest bottlenecks in fertility care."

Andrew Shine

stabilisation technology, the test extends sample viability from one hour to 72 hours, eliminating the logistical barriers of traditional clinic-based testing. Shine will focus on expanding Sapyen's footprint across clinics and healthcare networks, ensuring providers integrate Sapyen's at-home solution seamlessly into patient care.

"Andrew has spent his career transforming fertility and diagnostics businesses, taking innovative technologies and making them the standard of care," said Ashwin Ramachandran, CEO of Sapyen. "He has led market-defining commercial strategies, driven sustained revenue growth, and built some of the most impactful fertility services in Australia. His experience will be critical as we scale Sapyen and establish it as the cornerstone of male fertility testing."

Andrew has played a pivotal role in shaping the fertility and diagnostics industry in Australia. At Virtus Health, he led the expansion of its diagnostics division, driving multi-year double-digit revenue growth and increasing the role of genetic screening in IVF care. As CEO of Cryosite, he oversaw the strategic direction of Australia's first private cord blood and tissue stem cell storage company, navigating the commercial and regulatory landscape of a publicly listed biotech business. At Sonic Healthcare, he scaled genetic diagnostics testing nationwide, growing revenue at over three times the rate of traditional pathology services and expanding clinician adoption of cutting-edge testing. Most recently, as General Manager at City Fertility, Shine led commercial growth and operational strategy, strengthening the organisation's fertility services across Queensland.

Now, Andrew is bringing that experience to Sapyen at a pivotal moment. "Sapyen has solved one of the biggest bottlenecks in fertility care," said Andrew . "For too long, male fertility testing has been expensive, inconvenient, and tied to outdated clinic-based models. Sapyen eliminates those barriers, making high-quality testing more accessible than ever. The demand is clear, and my focus is ensuring every clinic and provider sees the value in integrating Sapyen into their care model."

The Sapyen Male Fertility Test Kit, powered by SPX72, is the first at-home test that extends sperm sample viability from one hour to 72 hours, allowing men to collect a sample at home and have it analysed in a world-class lab without compromising accuracy. With Andrew leading commercial sales, Sapyen is accelerating its expansion into new markets, strengthening industry partnerships, and setting a new benchmark for male fertility diagnostics.

ABOUT SAPYEN

Sapyen is a global leader in at-home male fertility testing, providing the world's first accurate, affordable, and convenient at-home sperm test. With its patent-pending SPX72 sperm stabilisation medium, Sapyen ensures high-quality samples and lab-quality results, making male fertility testing as accessible and straightforward as a home pregnancy test.

Ash Ramachandran Sapyen +61 413 333 655 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/794457456 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.